Literature DB >> 25385241

Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.

Apolonia Novillo1, Alicia Romero-Lorca, María Gaibar, Raoudha Bahri, Nourdin Harich, David Sánchez-Cuenca, Esther Esteban, Ana Fernández-Santander.   

Abstract

The genes CYP3A4 and CYP3A5 form part of a cluster of cytochrome P450 genes involved in drug metabolism reactions. The allelic variants of these genes CYP3A4*1B, CYP3A4*3, CYP3A4*17 and CYP3A5*3 have been linked both to the reduced catalytic activity of cytochromes and to prostate cancer risk in whites, though scarce data exist for North African populations. The main objective of this study was to describe CYP3A4*3, CYP3A4*17, CYP3A4*1B and CYP3A5*3 allele frequencies and haplotype variation in Moroccan Berbers and the general Tunisian population. The data obtained for the Tunisian participants were consistent with the European allele frequency ranges described, while Moroccan Berbers showed high frequencies of CYP3A4*17 (1.8%), CYP3A4*3 (8.5%) and the CYP3A4*1B/CYP3A5*3 haplotype (18.4%). This haplotype, linked to an increased risk of prostate cancer, was detected at a much higher frequency compared with the present Tunisian population (8.4%) or with reported frequencies for populations such as whites (0.6%) or African Americans (5.3%).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25385241     DOI: 10.5301/jbm.5000118

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  4 in total

1.  Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics.

Authors:  Yaya Kassogue; Brehima Diakite; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Zoumana Diarra; Mamoudou Maiga; Hind Dehbi; Sellama Nadifi; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Seydou Doumbia; Guimogo Dolo
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

2.  CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients.

Authors:  Effrosyni Mendrinou; Mohamed Elsayed Mashaly; Amir Mohamed Al Okily; Mohamed Elsayed Mohamed; Ayman Fathi Refaie; Essam Mahmoud Elsawy; Hazem Hamed Saleh; Hussein Sheashaa; George P Patrinos
Journal:  Front Pharmacol       Date:  2020-08-11       Impact factor: 5.810

3.  The prognostic value of differentially expressed CYP3A subfamily members for hepatocellular carcinoma.

Authors:  Tingdong Yu; Xiangkun Wang; Guangzhi Zhu; Chuangye Han; Hao Su; Xiwen Liao; Chengkun Yang; Wei Qin; Ketuan Huang; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-06-25       Impact factor: 3.989

Review 4.  A Review of Cancer Genetics and Genomics Studies in Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.